CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

The Logistics of Building a CAR-T Program

October 29th 2018

Patient Selection for CAR-T Therapy in NHL

October 29th 2018

CAR-T Safety & Post-Treatment Plans

October 29th 2018

Variations Among CAR T Products for NHL

October 29th 2018

Clinical Trials of CAR T-Cell Therapy in NHL

October 29th 2018

Clinical Data Surrounding CAR T-Cell Therapy in NHL

October 29th 2018

CAR T-Cell Therapies for Relapsed/Refractory NHL

October 29th 2018

Unmet Needs in Treating Relapsed NHL

October 29th 2018

Traditional Therapies for High-Risk Lymphoma and Efficacy

October 29th 2018

Reach of CAR T-Cell Therapy Poised to Extend in Oncology

October 26th 2018

Armin Ghobadi, MD, discusses the evolution and expansion of CAR T-cell therapy in oncology and how to maximize its application across liquid and solid tumors.

CD22 Emerges as CAR T-Cell Therapy Target

October 17th 2018

Although CD19 has proved to be an attractive and effective target for chimeric antigen receptor T-cell therapies in hematologic malignancies, a significant subset of patients treated with this groundbreaking form of immunotherapy eventually relapse.

Dr. Andreadis on Response to CAR T-Cell Therapy

October 16th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Expert Discusses Ongoing CAR T-Cell Research in Myeloma

October 9th 2018

Nina Shah, MD, discusses the present and future of chimeric antigen receptor T-cell therapy in myeloma.

Dr. Shah on the Current State of CAR T-Cell Therapy in Myeloma

October 9th 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the current state of CAR T-cell therapy in multiple myeloma.

Ongoing Efforts Seek to Refine, Expand CAR T-Cell Therapy

October 8th 2018

Brian Till, MD, discusses the rapidly evolving field of chimeric antigen receptor (CAR) T cells.

Dr. Raje on Quadruplet Regimens in Myeloma

October 1st 2018

Noopur Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, discusses the potential of quadruplet regimens in the multiple myeloma treatment paradigm.

Dr. Deol on the Safety of CAR T-Cell Therapy

September 28th 2018

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Dr. Smith Discusses Novel CAR T-Cell Therapies for Myeloma

September 27th 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Expert Considers Potential New Directions for CAR T-Cell Therapies

September 21st 2018

Abhinav Deol, MD, discusses the basics of chimeric antigen receptor T-cell therapy, potential new directions for these products, and the possible impact new products might have on the field.

CAR T-Cell Therapy Brings Hope to Relapsed/Refractory Myeloma

September 20th 2018

Eric Smith, MD, PhD, discusses the development of novel CAR T-cell therapies for patients with multiple myeloma.